Beyond castration and chemotherapy: Novel approaches to targeting androgen-driven pathways

Maturitas

Volumn 64, Issue 2, 2009, Pages 61-66

  Pal, Sumanta Kumar ^a   Twardowski, Przemyslaw ^a   Josephson, David Y ^b  

^a Division of Genitourinary Malignancies   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Abiraterone; Biologic therapy; Castrate resistant prostate cancer; Hormone refractory prostate cancer; MDV3100; Novel therapy; Phase III; Prostate cancer; Targeted therapy

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CYTOCHROME P450 17; KETOCONAZOLE; MDV 3100; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; UNCLASSIFIED DRUG;

ANDROGEN SYNTHESIS; BINDING AFFINITY; CANCER CHEMOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERTENSION; PRACTICE GUIDELINE; PROSTATE CANCER; RECEPTOR BINDING; REVIEW;

ANDROGEN ANTAGONISTS; ANDROGENS; ANDROSTENOLS; CASTRATION; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STEROID 17-ALPHA-HYDROXYLASE;

EID: 70349731955     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.08.004     Document Type: Review

References (39)

1. Huggins C., Stevens Jr. R.E., and Hodges C.V. Studies on prostate cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43 (1941) 209-223
2. Huggins C., and Hodges C.V. Studies on Prostatic Cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
3. Eisenberger M., O'Dwyer P., and Friedman M. Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. J Clin Oncol 4 (1986) 414-424
4. Aragon-Ching J.B., Williams K.M., and Gulley J.L. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 12 (2007) 4957-4971
5. Scher H., Liebertz C., Kelly W., et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 15 (1997) 2928-2938
6. Scher H., and Kelly W. Flutamide withdrawal syndrome: its impact on clinical trials in hormone- refractory prostate cancer. J Clin Oncol 11 (1993) 1566-1572
7. Small E.J., Halabi S., Dawson N.A., et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22 (2004) 1025-1033
8. Berthold D.R., Pond G.R., Soban F., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26 (2008) 242-245
9. Petrylak D.P., Tangen C.M., Hussain M.H.A., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
10. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (v.2.2009), available at http://www.nccn.org [accessed 29.07.09].
11. Bono J.S.D., Attard G., Reid A.H., et al. Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC). J Clin Oncol 26 May(Suppl.) (2008) [abstr. 5005]
12. Scher H.I., Beer T.M., Higano C.S., et al. Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). J Clin Oncol 27 Suppl. (2009) 15s [abstr. 5011]
13. Chan F.C.Y., Potter G.A., Barrie S.E., et al. 3- and 4-Pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P45017α (17α-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. J Med Chem 39 (1996) 3319-3323
14. McCague R., Rowlands M.G., Barrie S.E., et al. Inhibition of enzymes of estrogen and androgen biosynthesis by esters of 4-pyridylacetic acid. J Med Chem 33 (2002) 3050-3055
15. Rowlands M.G., Barrie S.E., Chan F., et al. Esters of 3-pyridylacetic acid that combine potent inhibition of 17alpha-hydroxylase/C17,20-lyase (cytochrome P45017alpha) with resistance to esterase hydrolysis. J Med Chem 38 (2002) 4191-4197
16. Attard G., Belldegrun A.S., and Bono J.S.D. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 96 (2005) 1241-1246
17. Miller W.L., Auchus R.J., and Geller D.H. The regulation of 17,20 lyase activity. Steroids 62 (1997) 133-142
18. Attard G., Reid A.H.M., Yap T.A., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26 (2008) 4563-4571
19. Barrie S.E., Potter G.A., Goddard P.M., et al. Pharmacology of novel steroidal inhibitors of cytochrome P45017[alpha] (17[alpha]-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 50 (1994) 267-273
20. Ryan C., Smith M.R., Rosenberg J.E., et al. Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer (CRPC). J Clin Oncol 26 May(Suppl.) (2008) [abstr. 5018]
21. Ryan C., Efstathiou E., Smith M., et al. Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol 27 Suppl. (2009) 15s [abstr. 5046]
22. Attard G., Reid A.H.M., A'Hern R., et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27 (2009) 3742-3748
23. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
24. Reid A.H., Attard G., Danila D., et al. A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts). J Clin Oncol 27 Suppl. (2009) 15s [abstr. 5047]
25. Danila D.C., Bono J.D., Ryan C.J., et al. Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto). J Clin Oncol 27 Suppl. (2009) 15s [abstr. 5048]
26. NCT00887198: abiraterone acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer, available at http://www.clinicaltrials.gov [accessed 29.07.09].
27. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 (2008) 1148-1159
28. NCT00638690: abiraterone acetate in castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy, available at http://www.clinicaltrials.gov [accessed 29.07.09].
29. LaTulippe E., Satagopan J., Smith A., et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62 (2002) 4499-4506
30. Tran C., Ouk S., Clegg N.J., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324 (2009) 787-790
31. Liu W., Xie C.C., Zhu Y., et al. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia 10 (2008) 897-907
32. Medivation, Inc. Home, available at http://www.medivation.com [accessed 29.07.09].
33. Fleisher M., Danila D.C., Leversha M., et al. Circulating tumor cells (CTC) in patients with metastatic castration-resistant prostate cancer (CRPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy. J Clin Oncol 27 Suppl. (2009) 15s [abstr. 5049]
34. Attar R.M., Balog A.J., Chen J., et al. Preclinical assessment of gene expression and proteomic profiles promoted by the novel antiandrogen BMS-641988, bicalutamide and castration. AACR Meeting Abstr. 2006 (2006) 1254
35. NCT00326586: a Phase I Dose-Escalation Study of BMS-641988 in patients with castration-resistant prostate cancer, available at http://www.clinicaltrials.gov [accessed 29.07.09].
36. NCT00644488: a Phase I Study of BMS-641988 in Japanese patients with castration resistant prostate cancer, available at http://www.clinicaltrials.gov [accessed 29.07.09].
37. Chen Y., Sawyers C.L., and Scher H.I. Targeting the androgen receptor pathway in prostate cancer. Current Opinion in Pharmacology 8 (2008) 440-448
38. Tatarov O., Mitchell T.J., Seywright M., et al. Src family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 15 (2009) 3540-3549
39. Yu E.Y., Wilding G., Posadas E., et al. Dasatinib in patients with hormone-refractory progressive prostate cancer: a phase II study. J Clin Oncol 26 May (Suppl.) (2008) [abstr. 5156]